Katinger HW - Search Results

1

Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, Lu H, Stiegler GM, Katinger HW, Jiang S, Broder CC, Dimitrov DS. Zhang MY, et al. Among authors: katinger hw. J Immunol Methods. 2006 Dec 20;317(1-2):21-30. doi: 10.1016/j.jim.2006.09.016. Epub 2006 Oct 16. J Immunol Methods. 2006. PMID: 17078964 Free PMC article.

2

Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion.

Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, Blumenthal R. Dimitrov AS, et al. Biochemistry. 2007 Feb 6;46(5):1398-401. doi: 10.1021/bi062245f. Biochemistry. 2007. PMID: 17260969

3

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.

Stiegler G, Katinger H. Stiegler G, et al. J Antimicrob Chemother. 2003 Apr;51(4):757-9. doi: 10.1093/jac/dkg172. Epub 2003 Mar 13. J Antimicrob Chemother. 2003. PMID: 12654737 Review. No abstract available.

4

Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.

Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Kunert R, et al. AIDS Res Hum Retroviruses. 2004 Jul;20(7):755-62. doi: 10.1089/0889222041524571. AIDS Res Hum Retroviruses. 2004. PMID: 15307922

5

Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5.

Kunert RE, Weik R, Ferko B, Stiegler G, Katinger H. Kunert RE, et al. AIDS. 2002 Mar 8;16(4):667-8. doi: 10.1097/00002030-200203080-00020. AIDS. 2002. PMID: 11873012

6

Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

Wolbank S, Kunert R, Stiegler G, Katinger H. Wolbank S, et al. J Virol. 2003 Apr;77(7):4095-103. doi: 10.1128/jvi.77.7.4095-4103.2003. J Virol. 2003. PMID: 12634368 Free PMC article.

7

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. Zwick MB, et al. J Virol. 2005 Jan;79(2):1252-61. doi: 10.1128/JVI.79.2.1252-1261.2005. J Virol. 2005. PMID: 15613352 Free PMC article.

8

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.

Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G. Nakowitsch S, et al. AIDS. 2005 Nov 18;19(17):1957-66. doi: 10.1097/01.aids.0000189856.13817.76. AIDS. 2005. PMID: 16260901 Clinical Trial.

9

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF. Joos B, et al. Antimicrob Agents Chemother. 2006 May;50(5):1773-9. doi: 10.1128/AAC.50.5.1773-1779.2006. Antimicrob Agents Chemother. 2006. PMID: 16641449 Free PMC article. Clinical Trial.

10

Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures.

Sack M, Paetz A, Kunert R, Bomble M, Hesse F, Stiegler G, Fischer R, Katinger H, Stoeger E, Rademacher T. Sack M, et al. FASEB J. 2007 Jun;21(8):1655-64. doi: 10.1096/fj.06-5863com. Epub 2007 Feb 27. FASEB J. 2007. PMID: 17327362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151 results

Search Page

Filters